Skip to main content

H. pylori infection and extra-gastroduodenal diseases

Abstract

Helicobacter pylori infection is the principal cause of peptic ulcer disease, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma. Recent studies have shown that it may interfere with many biological processes and determine or influence the occurrence of many diseases outside the stomach. Currently, the role of H. pylori in idiopathic thrombocytopenic purpura and iron deficiency anemia is well documented. Emerging evidence suggests that it may also contribute to vitamin B12 deficiency, insulin resistance, metabolic syndrome, diabetes mellitus and non-alcoholic liver disease. Additionally, it may increase the risk of acute coronary syndrome, cerebrovascular disease, neurodegenerative disease and other miscellaneous disorders. Different pathogenic mechanisms have been hypothesized, including the occurrence of molecular mimicry and the induction of a low-grade inflammation. This review summarizes the results of the most relevant studies on the extra-gastroduodenal manifestations of H. pylori infection.

Background

Helicobacter pylori infection is the principal cause of chronic gastritis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma [1, 2]. In recent decades, many articles have published on the fascinating topic of extragastroduodenal manifestations of H. pylori infection, including hematological, metabolic, cardiovascular, neurodegenerative and allergic disorders [3,4,5,6,7,8,9,10,11,12,13]. Different pathogenic mechanisms have been hypothesized, including the occurrence of molecular mimicry and the induction of a low-grade inflammation. Indeed, H. pylori infection is a very good model for studying host-bacterial interactions and very attractive for those interested in the role of gut microbiota in health and diseases. Here, we summarize the results of the most relevant studies on the extragastroduodenal manifestations of H. pylori infection.

Iron deficiency anemia

The link between Iron deficiency anemia (IDA) and H. pylori infection was reported firstly in 1991 by Blecker et al., who cured IDA of a 15 year-old female presenting with anemia-related syncope and H. pylori-induced chronic active hemorrhagic gastritis by eradication therapy without iron supplements [14]. The association of H. pylori infection with unexplained IDA has been proven in adult and pediatric populations [15, 16] though a few investigations didn’t show this link [17, 18]. Recently, Qu et al. conducted a meta-analysis of 15 case-control studies to investigate the relation between H. pylori infection and IDA [19]. H. pylori infection was diagnosed by endoscopy and histological examination in five studies, in which patients with peptic ulcer disease and gastric cancer were not included. The other 10 studies confirmed H. pylori infection by serology or urea breath test. The data showed an increased risk of IDA in patients with H. pylori infection with an odds ratio (OR) of 2.2 (95% confidence interval [CI]:1.5–3.2) [19]. Several works also demonstrated recovery from IDA by successful eradication of H. pylori without iron supplements [20]. Yuan et al. performed a meta-analysis of 16 randomized controlled trials involving 956 patients to assess the impact of H. pylori eradication therapy on IDA [21]. In this work, the diagnosis of H. pylori infection was based on rapid urease test or histology in eight studies, in which patients with peptic ulcer disease were excluded. The other eight studies confirmed H. pylori infection by urea breath test. The follow-up time in these studies ranged from 1 to 3 months. The difference from baseline to endpoint of hemoglobin, serum iron, and serum ferritin in the meta-analysis was statistically significantly different between anti-H. pylori treatment plus oral iron and oral iron alone (differences: Hb, 1.48 g/dL; serum iron: 1.15 mol/L; serum ferritin, 1.84 ng/mL) [21].

H. pylori causes IDA by several mechanisms. First, increased iron loss can be due to hemorrhagic gastritis, peptic ulcer disease and gastric adenocarcinoma [22]. Second, CagA protein of H. pylori has been shown to participate in iron acquisition from interstitial holotransferrin [23]. Iron uptake by H. pylori is enhanced during the growth of the bacteria [24]. Third, H. pylori-related corporal gastritis may decrease acid secretion due to gland atrophy and results in the reduction of iron absorption from diet [25].

In summary, the association of H. pylori and IDA has been conclusively proven in numerous studies. Current international and national guidelines recommend eradication of H. pylori infection in patients with unexplained IDA [26, 27].

Immune thrombocytopenic purpura

Gasbarrini et al. reported the first case of H. pylori infection associated with immune thrombocytopenic purpura (ITP) in 1998 [28]. An observation study from Japan also found a good platelet response in ITP patients treated by H. pylori eradication [29]. A randomized controlled trial by Brito et al. revealed that H. pylori eradication resulted in a significant platelet response in children and adolescents affected by ITP [30]. The role of H. pylori infection in ITP has also been confirmed by several other studies [31, 32]. Nonetheless, some studies from countries with low prevalence of infection, like France and the United States, did not find the link between H. pylori infection and ITP [33, 34]. Recently, Stasi et al. conducted a meta-analysis of 25 studies to investigate the impact of anti-H. pylori therapy on ITP [34]. The assessing time for platelet response ranged from one to six months. The data showed that the rates of complete response (platelet count 100 × 109/L) and overall response (platelet count 30 × 109/L and at least doubling of the basal count) after successful eradication of H. pylori were 42.7 and 50.3%, respectively [35]. The predictors of a good response to eradication therapy were countries with higher prevalence of H. pylori infection (such as Japan and Italy) and patients with milder degree of thrombocytopenia [35]. In the majority of ITP patients responding to anti-H. pylori therapy, the durability of platelet response is more than 7 years, indicating the disease is cured [36]. Another meta-analysis by Arnold et al. performed a meta-analysis to determine the effect of H. pylori eradication therapy in patients with ITP by comparing the platelet response in ITP patients with and without H. pylori infection [37]. The odds of achieving a platelet count response following eradication therapy were 14.5 higher (95% CI: 4.2 to 83.0) in patients with H. pylori infection than in those without infection (response rate: 51.2% vs. 8.8%). These findings strengthen the causal association between H. pylori infection and ITP. Several mechanisms regarding H. pylori-associated ITP have been proposed [38]. One intriguing hypothesis concerning molecular mimicry is that cross-reactive antibodies are produced that react both H. pylori components and platelet surface antigens. Takahashi et al. showed that platelet elutes from H. pylori-infected ITP patients recognized CagA protein in immunoblots, but those from H. pylori-infected non-ITP patients did not [39]. Bai et al. also reported that monoclonal antibodies generated against H. pylori urease B react with GP IIb/IIIa expressed on the platelet surface [40]. While these findings suggest molecular mimicry between H. pylori components and platelet surface antigens, the exact pathogenic roles of these cross-reactive antibodies remain obscure. In another potential mechanism, H. pylori infection may alter Fcγ receptor balance of moncytes/macrophages and induce autoantibody formation. A recent study showed that the FcγR II B expression on circulating monocytes was down-regulated in H. pylori-infected ITP patients [41]. Therefore, H. pylori may alter Fcγ receptor balance of moncytes/macrophages through downregulation of the inhibitory receptor FcγR II B.

In conclusion, many studies support the association between H. pylori infection and ITP. Current international and national guidelines recommend that H. pylori infection should be sought and treated in patients with ITP [27].

Vitamin B12 deficiency

The link between vitamin B12 deficiency and H. pylori infection was reported firstly in 1984 by O’Connor et al. who showed Campylobacter-like organisms in patients with type A gastritis and pernicious anemia [42]. Studies have demonstrated a link between chronic H. pylori infection and malabsorption of vitamin B12 [43]. Sarari et al. showed that vitamin B12 deficiency was present in 67.4% (29/43) of the patients with H. pylori infection [44]. Shuval-Sudai et al. found a higher prevalence of H. pylori infection in patients at the lower end of the normal range of serum vitamin B12 levels [45]. However, most studies regarding the association between vitamin B12 and H. pylori infection focus on testing H. pylori status and measuring serum levels of vitamin B12. No adequate interventional studies proving the effect of anti-H. pylori therapy on vitamin B12 deficiency exist.

Metabolic syndrome and diabetes mellitus (DM)

Many epidemiological studies have supported a link between insulin resistance, metabolic syndrome and H. pylori infection [46, 47]. Chen et al. demonstrated that H. pylori-infected subjects had a higher prevalence of metabolic syndrome than those without H. pylori infection [48]. Additionally, Yang et al. showed a significant association between H. pylori infection and DM [49]. Similar results were also observed by other investigators [50]. Furthermore, Horikawa et al. revealed that H. pylori infection worsened glycemia control in diabetic patients [51]. Polyzos et al. conducted a systemic review including nine studies and showed a trend toward a positive association between H. pylori infection and insulin resistance [47]. In contrast, several studies did not find the link between H. pylori infection and insulin resistance or metabolic syndrome [52]. Naja et al. showed no association between H. pylori infection and metabolic syndrome in a Lebanese population [53]. A meta-analysis of 18 studies found no strong correlation between H. pylori infection and serum concentrations of total cholesterol and triglyceride [54]. Wada et al. also found that successful eradication of H. pylori could not improve glucose control of DM in Japanese patients [55]. Furthermore, a recent randomized controlled trial involving 49 H. pylori-infected subjects in a prediabetes stage showed that H. pylori eradication resulted in an increased Homeostatic model assessment of insulin resistance (HOMA-IR) [56].

Several studies reported a reverse link between H. pylori infection and obesity [57,58,59,60]. A case-control study from Taiwan demonstrated an inverse relationship between morbid obesity and H. pylori seropositivity [57]. An ecological study also showed an inverse correlation between H. pylori prevalence and rate of overweight/obesity in countries of the developed world [58]. However, a large case-control study including 8820 participants from China showed body mass index was significantly and positively associated with H. pylori infection [59]. An intervention trial demonstrated serum ghrelin concentrations were inversely related to the severity of H. pylori-associated gastritis in prepubertal children [60]. Eradication of H. pylori infection resulted in a significant increase in body mass index along with a significant decrease in circulating ghrelin levels and an increase in leptin levels [60].

In summary, the issue of the association between H. pylori infection and metabolic syndrome or DM remains contradictory.

Nonalcoholic fatty liver disease (NAFLD)

A cohort study by Kim et al. demonstrated that the subjects with H. pylori infection had a higher incidence of NAFLD than those without infection (hazard ratio: 1.21 [95% CI: 1.1–1.3]) [61]. Polyzos et al. also revealed that patients with NAFLD had higher anti-H. pylori IgG titers, together with lower circulating adiponectin and higher tumor necrosis factor-α levels, compared to non-NAFLD subjects [62]. However, opposite results from Korea and Japan showed no association between H. pylori infection and NAFLD [63, 64]. Recently, a meta-analysis demonstrated a significantly increased risk of NAFLD in patients with H. pylori infection [65]. Nonetheless, the mechanism underlying the association between H. pylori infection and NAFLD remains unclear, and interventional studies proving the effect of anti-H. pylori therapy on NAFLD are fairly limited.

In summary, the association between H. pylori infection and NAFLD remains contradictory.

Coronary artery disease (CAD)

Mendall et al. first showed a link between H. pylori and CAD in 1994 [66]. Several studies reported that CagA-postive strains of H. pylori were associated with atherosclerosis [67,68,69]. Al-Ghamdi et al found that H. pylori plays an important role in the development of CAD by altering the lipid profile and enhancement of chronic inflammation [70]. Figura et al. also revealed that CagA-postive strains of H. pylori were associated with high serum levels of interleukin-6 and B-type natriuretic peptide in patients with CAD [71]. A nationwide retrospective cohort study demonstrated that H. pylori infection increased the risk of acute coronary syndrome [72]. In addition, a meta-analysis of 26 studies involving more than 20,000 patients also showed a significant association between H. pylori infection and the risk of myocardial infarction (OR: 2.10; 95% CI: 1.8–2.5) [73]. However some studies from Indian and German did not find the association between H. pylori and CAD [74, 75]. Additionally, there are still no interventional studies proving the beneficial effect of H. pylori eradication in decreasing the incidence of CAD.

There are several proposed mechanisms underlying the association between H. pylori infection and CAD. H. pylori has been detected in human carotid atherosclerotic plaques [76]. Oshima et al. demonstrated the association of H. pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects [77]. They proposed that H. pylori infection may cause atherogenesis through persistent low-grade inflammation. Recently, molecular mimicry between CagA antigen of H. pylori and atherosclerotic plaque peptides has also been proposed as a possible mechanism [78].

In conclusion, there is controversial evidence linking H. pylori infection and CAD. No adequate interventional trials demonstrating a lower incidence of CAD as a result of anti-H. pylori therapy exit.

Cerebrovascular disease

Wincup et al. first reported a link between H. pylori infection and stroke in 1996 (OR = 1.57, 95% CI 0.95 to 2.60) [79]. A Mexican study found that levels of antibodies to H. pylori predict incident stroke in fully adjusted models (OR: 1.58; 95% CI: 1.1 to 2.3) [80]. Recently, Wang et al. performed a meta-analysis of 4041 Chinese patients, and found an association between H. pylori infection and non-cardioembolic stroke [81]. However, a cohort study of 9895 cases from the United States found a reverse link between H. pylori infection and stroke mortality, and this reverse association was stronger for H. pylori cagA positivity [82]. In summary, there is controversial evidence linking H. pylori infection and cerebrovascular disease.

Other miscellaneous disorders

Some studies also disclosed the relationship of H. pylori with dementia and Alzheimer’s disease (AD) [83, 84]. A study in Greece by Kountouras et al. found higher prevalence of H. pylori infection in patients with AD than in the control group [85]. Hung et al. designed a study for the relationship between H. pylori infection and non-Alzheimer’s dementia (non-AD) using a nationwide population-based dataset in Taiwan, and found that patients with H. pylori infection were 1.6-fold more likely to develop non-AD than those without infection [83]. A retrospective cohort study using nationwide database in Taiwan showed that eradication of H. pylori was associated with a decreased progression of dementia as compared to no eradication of H. pylori in AD patients with peptic ulcers [86]. However, further prospective randomized control trials are needed to clarify these findings.

The inverse relationship between H. pylori infection and allergic asthma has been reported. A meta-analysis by Zhou et al... in 2013 found lower prevalence rate of H. pylori infection in patients with allergic asthma [87]. Higher prevalence rate of H. pylori infection has been found in cirrhotic patients with hepatoencephalopathy than in those without hepatoencephalopathy [88]. Jaing et al also showed the association of H. pylori infection with elevated blood ammonia levels in cirrhotic patients [89]. Several studies have also reported that H. pylori infection increases the risk of colon adenocarcinoma and adenoma [90,91,92]. Recently, an association between H. pylori infection and chronic spontaneous urticaria has been reported but remains controversial. Fukuda et al. demonstrated a significant improvement of chronic spontaneous urticaria by anti-H. pylori therapy in Japanese patients [93]. This work was consistent with a systemic review of 10 studies by Federman et al. [94]. However, Moreira et al. did not find the association between H. pylori infection and chronic spontaneous urticaria [95].

In summary, there are still controversial evidences linking H. pylori infection and aforementioned miscellaneous disorders. Adequate interventional trials are needed to clarify these associations.

Conclusions

Recent studies have shown that H. pylori may interfere with many biological processes and determine or influence the occurrence of many diseases outside the stomach (Table 1 and Fig. 1). Currently, its role in ITP and IDA is well documented. Emerging evidence suggests that it may also contribute to vitamin B12 deficiency, insulin resistance, metabolic syndrome, diabetes mellitus and non-alcoholic liver disease. Additionally, it may also increase the risk of acute coronary syndrome, cerebrovascular disease, and neurodegenerative disease, H. pylori infection is a perfect model for the study of interplay between human beings and bacteria. Further studies are mandatory to clarify the pathogenesis of extragastroduodenal diseases induced by H. pylori infection.

Table 1 The relevant studies on the associations between H. pylori infection and extra-gastroduodenal diseases
Fig. 1
figure1

The possible mechanism for the association between H. pylori infection and extra-gasroduodenal diseases

Abbreviations

AD:

Alzheimer’s disease

CI:

Confidence interval

DM:

Diabetes mellitus

IDA:

Iron deficiency anemia

ITP:

Immune thrombocytopenic purpura

NAFLD:

Nonalcoholic fatty liver disease

OR:

Odds ratio

References

  1. 1.

    Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–86.

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148(4):719–31.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Realdi G, Dore MP, Fastame L. Extradigestive manifestations of helicobacter pylori infection: fact and fiction. Dig Dis Sci. 1999;44(2):229–36.

    Article  PubMed  CAS  Google Scholar 

  4. 4.

    Suzuki H, Franceschi F, Nishizawa T, et al. Extragastric manifestations of helicobacter pylori infection. Helicobacter. 2011;16(Suppl 1):65–9.

    Article  PubMed  Google Scholar 

  5. 5.

    Banic M, Franceschi F, Babic Z, et al. Extragastric manifestations of helicobacter pylori infection. Helicobacter. 2012;17(Suppl 1):49–55.

    Article  PubMed  Google Scholar 

  6. 6.

    Deng B, Li Y, Zhang Y, et al. Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis. Carcinogenesis. 2013;34(6):1189–95.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Papagiannakis P, Michalopoulos C, Papalexi F, et al. The role of helicobacter pylori infection in hematological disorders. Eur J Intern Med. 2013;24(8):685–90.

    Article  PubMed  Google Scholar 

  8. 8.

    Buzas GM. Metabolic consequences of helicobacter pylori infection and eradication. World J Gastroenterol. 2014;20(18):5226–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. 9.

    Campuzano-Maya G. Hematologic manifestations of helicobacter pylori infection. World J Gastroenterol. 2014;20(36):12818–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. 10.

    Franceschi F, Tortora A, Gasbarrini G, et al. Helicobacter pylori and extragastric diseases. Helicobacter. 2014;19(Suppl 1):52–8.

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Franceschi F, Zuccala G, Roccarina D, et al. Clinical effects of helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol. 2014;11(4):234–42.

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of helicobacter pylori: a concise review. World J Gastroenterol. 2014;20(34):11950–61.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Chmiela M, Gajewski A, Rudnicka K. Helicobacter pylori vs coronary heart disease - searching for connections. World J Cardiol. 2015;7(4):187–203.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Blecker U, Renders F, Lanciers S, et al. Syncopes leading to the diagnosis of a helicobacter pylori positive chronic active haemorrhagic gastritis. Eur J Pediatr. 1991;150(8):560–1.

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Ortiz M, Rosado-Carrion B, Bredy R. Role of helicobacter pylori infection in Hispanic patients with anemia. Bol Asso Med P R. 2014;106:13–8.

    Google Scholar 

  16. 16.

    Sato Y, Yoneyama O, Azumaya M, et al. The relationship between iron deficiency in patients with helicobacter pylori-infected nodular gastritis and the serum prohepcidin level. Helicobacter. 2015;20:11–8.

    Article  PubMed  CAS  Google Scholar 

  17. 17.

    Bazmamoun H, Razavi Z, Esfahani H, et al. Evaluation of iron deficiency anemia and BMI in children suffering from helicobacter pylori infection. Iran J Ped Hematol Oncol. 2014;4:167–71.

    PubMed  PubMed Central  CAS  Google Scholar 

  18. 18.

    Sandstrom G, Rodjer S, Kaijser B, et al. Helicobacter pylori antibodies and iron deficiency in female adolescents. PLoS One. 2014;9:e113059.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. 19.

    Qu XH, Huang XL, Xiong P, et al. Does helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis World J Gastroenterol. 2010;16(7):886–96.

    PubMed  CAS  Google Scholar 

  20. 20.

    Annibale B, Marginani M, Monarca B, et al. Reversal of iron deficiency anemia after helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med. 1999;131:668–72.

    Article  PubMed  CAS  Google Scholar 

  21. 21.

    Yuan W, Li Y, Yang K, et al. Iron deficiency anemia in helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010;45(6):665–76.

    Article  PubMed  CAS  Google Scholar 

  22. 22.

    Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. J Dig Dis. 2012;13:342–9.

  23. 23.

    Boyanova L. Role of helicobacter pylori virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011;6(8):843–6.

    Article  PubMed  CAS  Google Scholar 

  24. 24.

    Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systemic review and meta-analysis. Helicobacter. 2008;13:323–40.

    Article  PubMed  CAS  Google Scholar 

  25. 25.

    Capurso G, Lahner E, Marcheggiano A, et al. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15:1753–61.

    Article  PubMed  CAS  Google Scholar 

  26. 26.

    Goddard AF, James MW, Mclntyre AS, et al. Guidelines for the management of iron deficiency anemia. Gut. 2011;60:1309–16.

    Article  PubMed  CAS  Google Scholar 

  27. 27.

    Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence consensus report. Gut. 2012;61(5):646–64.

    Article  PubMed  CAS  Google Scholar 

  28. 28.

    Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of helicobacter pylori. Lancet. 1998;352(9131):878.

    Article  PubMed  CAS  Google Scholar 

  29. 29.

    Kikuchi T, Kobayashi T, Yamashita T, et al. Eight-year follow-up of patients with immune thrombocytopenic purpura related toH. Pyloriinfection. Platelets. 2011;22(1):61–4.

    Article  PubMed  CAS  Google Scholar 

  30. 30.

    Brito HS, Braga JA, Loggetto SR, et al. Helicobacter pylori infection and immune thrombocytopenia purpura in children and adolescents: a randomized controlled trial. Platelet. 2014;15:1–6.

    Google Scholar 

  31. 31.

    Kim H, Lee WS, Lee KH, et al. Efficacy of helicobacter pylori eradication for the 1st-line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. AnnHematol. 2015;94:939–46.

    Google Scholar 

  32. 32.

    Noonavath RN, Lakshmi CP, Dutta TK, et al. Helicobacter pylori eradication in patients with chronic immune thrombocytopenic purpura. World J Gastroenterol. 2014;20:6918–23.

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Michel M, Cooper N, Jean C, et al. Does helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood. 2004;103(3):890–6.

    Article  PubMed  CAS  Google Scholar 

  34. 34.

    Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic purpura and helicobacter pylori infection. Arch Intern Med. 2002;162(9):1033–6.

    Article  PubMed  Google Scholar 

  35. 35.

    Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231–40.

    Article  PubMed  CAS  Google Scholar 

  36. 36.

    Tsumoto C, Tominaga K, Okazaki H, et al. Long-term efficacy of helicobacter pylori eradication in patients with idiopathic thrombocytopenia purpura: 7-year follow-up prospective study. Ann Hematol. 2009;88:789–93.

    Article  PubMed  CAS  Google Scholar 

  37. 37.

    Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. Pylori treatment in patients with immune thrombocytopenic purpura with and without H. Pylori infection: a systematic review. Haematologica. 2009;94(6):850–6.

    Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol. 2014;20:714–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. 39.

    Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by helicobacter pylori CagA protein may be involved in the pathogenesis of H. Pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124:91–6.

    Article  PubMed  CAS  Google Scholar 

  40. 40.

    Bai Y, Wang Z, Bai X, et al. Cross reaction of antibody against helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol. 2009;89:142–9.

    Article  PubMed  CAS  Google Scholar 

  41. 41.

    Wu Z, Zhou J, Prsoon P, et al. Low expression of FCCRIIB in macrophages of immune thrombocytopenia-affected individuals. Int J Hematol. 2012;96:588–93.

    Article  PubMed  CAS  Google Scholar 

  42. 42.

    O'Connor HJ, Axon AT, Dixon MF. Campylobacter-like organisms unusual in type a (pernicious anaemia) gastritis. Lancet. 1984;2(8411):1091.

    Article  PubMed  CAS  Google Scholar 

  43. 43.

    Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368:2041–2.

    Article  PubMed  CAS  Google Scholar 

  44. 44.

    Sarari AS, Farraj MA, Hamoudi W, et al. Helicobacter pylori, a causative agent of vitamin B12 deficiency. J Infect Dev Ctries. 2008;2(5):346–9.

    PubMed  Google Scholar 

  45. 45.

    Shuval-Sudai O, Granot E. An association between helicobacter pylori infection and serum vitamin B12 levels in healthy adults. J Clin Gastroenterol. 2003;36(2):130–3.

    Article  PubMed  CAS  Google Scholar 

  46. 46.

    Eshraghian A, Hashemi SA, Hamidian Jahromi A, et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci. 2009;54(9):1966–70.

    Article  PubMed  Google Scholar 

  47. 47.

    Polyzos SA, Kountouras J, Zavos C, et al. The association between helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011;16(2):79–88.

    Article  PubMed  CAS  Google Scholar 

  48. 48.

    Chen TP, Hung HF, Chen MK, et al. Helicobacter pylori infection is positively associated with metabolic syndrome in Taiwanese adults: a cross-sectional study. Helicobacter. 2015;20:184–91.

    Article  PubMed  CAS  Google Scholar 

  49. 49.

    Yang GH, Wu JS, Yang YC, et al. Gastric helicobacter pylori infection associated with risk of diabetes mellitus, but not prediabetes. J Gastroenterol Hepatol. 2014;29:1794–9.

    Article  PubMed  Google Scholar 

  50. 50.

    Bajai S, Rekwal L, Misra SP, et al. Association of Helicobacter pylori infection in patients with type 2 diabetes. Indian J Endocrinol Metab. 2014;18:694–9.

    Google Scholar 

  51. 51.

    Horikawa C, Kodama S, Fujihara K, et al. High risk of failing eradication of helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106:81–7.

    Article  PubMed  Google Scholar 

  52. 52.

    Gillum RF. Infection with helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the third National Health and nutrition examination survey. J Natl Med Assoc. 2004;96:1470–6.

    PubMed  PubMed Central  Google Scholar 

  53. 53.

    Naja F, Nasreddine L, Hwalla N, et al. Association of H. Pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter. 2012;17(6):444–51.

    Article  PubMed  CAS  Google Scholar 

  54. 54.

    Danesh J, Peto R. Risk factors for coronary heart disease and infection with helicobacter pylori: meta-analysis of 18 studies. BMJ. 1998;316:1130–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. 55.

    Wada Y, Hamamoto Y, Kawasaki Y, et al. The eradication of helicobacter pylori does not affect glycemic control in Japanese subjects with type 2 diabetes. Jpn Clin Med. 2013;4:41–3.

    PubMed  PubMed Central  CAS  Google Scholar 

  56. 56.

    Kachuei A, Amini M, Sebghatollahi V, et al. Effect of helicobacter pylori eradication on insulin resistance among prediabetic patients: a pilot study and single-blind randomized controlled clinical trial. J Res Med Sci. 2016;21:8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. 57.

    Wu MS, Lee WJ, Wang HH, et al. A case-control study of association of helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med. 2005;165:1552–5.

    Article  PubMed  Google Scholar 

  58. 58.

    Lender N, Talley NJ, Enck P, et al. Associations between helicobacter pylori and obesity--an ecological study. Aliment Pharmacol Ther. 2014;40:24–31.

    Article  PubMed  CAS  Google Scholar 

  59. 59.

    Xu C, Yan M, Sun Y, et al. Prevalence of helicobacter pylori infection and its relation with body mass index in a Chinese population. Helicobacter. 2014;19:437–42.

    Article  PubMed  Google Scholar 

  60. 60.

    Pacifico L, Anania C, Osborn JF, et al. Long-term effects of helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. Eur J Endocrinol. 2008;158:323–32.

    Article  PubMed  CAS  Google Scholar 

  61. 61.

    Kim TJ, Sinn DH, Min YW, et al. A cohort study on helicobacter pylori infection associated with non-alcoholic fatty liver disease. J Gastroenterol. 2017;52(11):1201–10.

    Article  PubMed  Google Scholar 

  62. 62.

    Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62:121–6.

    Article  PubMed  CAS  Google Scholar 

  63. 63.

    Okushin K, Takahashi Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol. 2015;15:25.

    Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Tang DM, Kumar S. The association between helicobacter pylori infection and nonalcoholic liver disease. Curr Gastroenterol Rep. 2017;19:5.

    Article  PubMed  Google Scholar 

  65. 65.

    Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Helicobacter pylori and risk of nonalcoholic fatty liver disease: a systemic review and meta-analysis. J Gastroenerol. 2017; Jan 17; https://doi.org/10.1097/MCG.0000000000000784.

  66. 66.

    Mendall MA, Goggin PM, Molineaux N, et al. Relation of helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71(5):437–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. 67.

    Mayr M, Kiechl S, Mendall MA, Willeit J, Wick G, Xu QB. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains prospective results from the Bruneck study. Stroke. 2003;34:610–5.

  68. 68.

    Park MJ, Choi SH, Kim D, et al. Association between helicobacter pylori Seropositivity and the coronary artery calcium score in a screening population. Gut Liver. 2011;5(3):321–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. 69.

    Huang B, Chen Y, Xie Q, et al. CagA-positive helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. Dig Dis Sci. 2011;56(1):109–14.

    Article  PubMed  CAS  Google Scholar 

  70. 70.

    Al-Ghamdi A, Jiman-Fatani AA, El-Banna H. Role of chlamydia pneumoniae, helicobacter pylori and cytomegalovirus in coronary artery disease. Pak J Pharm Sci. 2011;24(2):95–101.

    PubMed  Google Scholar 

  71. 71.

    Figura N, Palazzuoli A, Vaira D, et al. Cross-sectional study: CagA-positive helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol. 2014;67(3):251–7.

    Article  PubMed  CAS  Google Scholar 

  72. 72.

    Lai CY, Yang TY, Lin CL, et al. Helicobacter pylori infection and the risk of acute coronary syndrome: a nationwide retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2015;34:69–74.

    Article  PubMed  Google Scholar 

  73. 73.

    Yu XJ, Yang X, Feng L, et al. Association between helicobacter pylori infection and angiographically demonstrated coronary artery disease: a meta-analysis. Exp Ther Med. 2017;13:787–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. 74.

    Padmavati S, Gupta U, Agarwal HK. Chronic infections & coronary artery disease with special reference to Chalmydia pneumoniae. Indian J Med Res. 2012;135(2):228–32.

    PubMed  PubMed Central  CAS  Google Scholar 

  75. 75.

    Schottker B, Adamu MA, Weck MN, et al. Helicobacter pylori infection, chronic atrophic gastritis and major cardiovascular events: a population-based cohort study. Atherosclerosis. 2012;220(2):569–74.

    Article  PubMed  CAS  Google Scholar 

  76. 76.

    Ameriso SF, Fridman EA, Leiguarda RC, et al. Detection of helicobacter pylori in human carotid atherosclerotic plaques. Stroke. 2001;32:385–91.

    Article  PubMed  CAS  Google Scholar 

  77. 77.

    Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol. 2005;45:1219–22.

    Article  PubMed  CAS  Google Scholar 

  78. 78.

    Kucukazman M, Yavuz B, Sacikara M, et al. The relationship between updated Sydney system score and LDL cholesterol levels in patients infected with helicobacter pylori. Dig Dis Sci. 2009;54:604–7.

    Article  PubMed  CAS  Google Scholar 

  79. 79.

    Whincup PH, Mendall MA, Perry IJ, et al. Prospective relations between helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart. 1996;75(6):568–72.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. 80.

    Sealy-Jefferson S, Gillespie BW, Aiello AE, et al. Antibody levels to persistent pathogens and incident stroke in Mexican Americans. PLoS One. 2013;8(6):e65959.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. 81.

    Wang ZW, Li Y, Huang LY, et al. Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis. J Neurol. 2012;259(12):2527–37.

    Article  PubMed  Google Scholar 

  82. 82.

    Chen Y, Segers S, Blaser MJ. Association between helicobacter pylori and mortality in the NHANES III study. Gut. 2013;62(9):1262–9.

    Article  PubMed  Google Scholar 

  83. 83.

    Huang WS, Yang TY, Shen WC, et al. Association between helicobacter pylori infection and dementia. J Clin Neurosci. 2014;21(8):1355–8.

    Article  PubMed  CAS  Google Scholar 

  84. 84.

    Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009;5(4):348–60.

    Article  PubMed  Google Scholar 

  85. 85.

    Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between helicobacter pylori infection and Alzheimer disease. Neurology. 2006;66(6):938–40.

    Article  PubMed  CAS  Google Scholar 

  86. 86.

    Chang YP, Chiu GF, Kuo FC, et al. Eradication of helicobacter pylori is associated with the progression of dementia: a population-based study. Gastroenterol Res Pract. 2013;2013:175729.

    Article  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Zhou X, Wu J, Zhang G. Association between helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25(4):460–8.

    Article  PubMed  CAS  Google Scholar 

  88. 88.

    Hu BL, Wang HY, Yang GY. Association of Helicobacter pylori infection with hepatic encephalopathy risk: a systematic review. Clin Res Hepatol Gastroenterol. 2013;37(6):619–25.

    Article  PubMed  Google Scholar 

  89. 89.

    Jiang HX, Qin SY, Min ZG, et al. Association of Helicobacter pylori with elevated blood ammonia levels in cirrhotic patients: a meta-analysis. Yonsei Med J. 2013;54(4):832–8.

    Article  PubMed  PubMed Central  Google Scholar 

  90. 90.

    Zhang Y, Hoffmeister M, Weck MN, et al. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol. 2012;175(5):441–50.

    Article  PubMed  Google Scholar 

  91. 91.

    Wu Q, Yang ZP, Xu P, et al. Association between helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Color Dis. 2013;15(7):e352–64.

    Article  CAS  Google Scholar 

  92. 92.

    Chen YS, Xu SX, Ding YB, et al. Helicobacter pylori infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev. 2013;14(12):7613–9.

    Article  PubMed  Google Scholar 

  93. 93.

    Fukuda S, Shimoyama T, Umegaki T, et al. Effect of helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria. J Gastroenterol. 2004;39(9):827–30.

    Article  PubMed  Google Scholar 

  94. 94.

    Federman DG, Kirsner RS, Moriarty JP, et al. The effect of antibiotic therapy for patients infected with helicobacter pylori who have chronic urticaria. J Am Acad Dermatol. 2003;49(5):861–4.

    Article  PubMed  Google Scholar 

  95. 95.

    Moreira A, Rodrigues J, Delgado L, et al. Is helicobacter pylori infection associated with chronic idiopathic urticaria? Allergol Immunopathol (Madr). 2003;31(4):209–14.

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Drs. PIH and FWT reviewed the articles and wrote the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Ping-I Hsu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tsay, F., Hsu, P. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci 25, 65 (2018). https://doi.org/10.1186/s12929-018-0469-6

Download citation

Keywords

  • Helicobacter pylori
  • Iron deficiency anemia
  • Idiopathic thrombocytopenic purpura and vitamin B12 deficiency